Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. The evidence-based reduction in risk of microvascular disease with glucose lowering has resulted in guidelines worldwide recommending optimisation of glycosylated haemoglobin, but no trial results have shown unequivocal cardio...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
If you are the owner of this record, you can report an update to it here: Report update to this record